Essential Role of NMDA Receptor Channel ε4 Subunit (GluN2D) in the Effects of Phencyclidine, but Not Methamphetamine by Hagino, Yoko et al.
Essential Role of NMDA Receptor Channel e4 Subunit
(GluN2D) in the Effects of Phencyclidine, but Not
Methamphetamine
Yoko Hagino
1, Shinya Kasai
1, Wenhua Han
1, Hideko Yamamoto
1, Toshitaka Nabeshima
2, Masayoshi
Mishina
3, Kazutaka Ikeda
1*
1Division of Psychobiology, Tokyo Institute of Psychiatry, Tokyo, Japan, 2Comparative Cognitive Science Institutes and Department of Chemical Pharmacology, Graduate
School of Pharmaceutical Sciences, Meijo University, Nagoya, Japan, 3Department of Molecular Neurobiology and Pharmacology, Graduate School of Medicine, The
University of Tokyo, Tokyo, Japan
Abstract
Phencyclidine (PCP), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, increases locomotor activity in
rodents and causes schizophrenia-like symptoms in humans. Although activation of the dopamine (DA) pathway is
hypothesized to mediate these effects of PCP, the precise mechanisms by which PCP induces its effects remain to be
elucidated. The present study investigated the effect of PCP on extracellular levels of DA (DAex) in the striatum and
prefrontal cortex (PFC) using in vivo microdialysis in mice lacking the NMDA receptor channel e1o re4 subunit (GluRe1
[GluN2A] or GluRe4 [GluN2D]) and locomotor activity. PCP significantly increased DAex in wildtype and GluRe1 knockout
mice, but not in GluRe4 knockout mice, in the striatum and PFC. Acute and repeated administration of PCP did not increase
locomotor activity in GluRe4 knockout mice. The present results suggest that PCP enhances dopaminergic transmission and
increases locomotor activity by acting at GluRe4.
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Introduction
Phencyclidine (PCP) is a drug of abuse that causes psychosis
resembling both the positive (e.g., hallucinations, paranoia) and
negative (e.g., emotional withdrawal, motor retardation) signs of
schizophrenia in humans [1]. Acute administration of PCP to
rodents produces increases in locomotor activity, stereotypy, and
ataxia [2,3]. Repeated PCP administration produces sensitization of
locomotor activity, rearing, and stereotypy but tolerance to ataxia
[3–5]. PCP acts as a noncompetitive antagonist of the N-methyl-D-
aspartate (NMDA) excitatory amino acid receptor [6–8]. Addition-
ally, high doses of PCP block dopamine (DA) reuptake [1,9–11].
Similar to PCP, amphetamine (AMPH) and its derivative
methamphetamine (METH) produce behavioral sensitization to
locomotoractivity,rearing,andstereotypywhentheyarerepeatedly
administered [12,13]. Amphetamine and METH facilitate dopa-
minergic neurotransmission via a number of mechanisms [14],
including DA efflux by reverse transport through the dopamine
transporter (DAT) [15–18], inhibition of DA uptake [19–21], and
inhibition of monoamine oxidase (MAO) activity [22–24].
The NMDA receptor channel subunit family is composed of
seven subunits—GluRf (GluN1), GluRe1-4 (GluN2A-D), and
GluRx1, 2 (GluN3A, B)—which are all products of separate genes
[25]. In the rodent and human brains, GluRe1 and GluRe2 are
predominant subunits expressed in the forebrain. GluRe3i s
expressed largely in cerebellar granule cells and selectively in
several other brain regions. GluRe4 is expressed in the
diencephalon and midbrain and is more prominent during early
development [26]. Highly active NMDA receptor channels are
produced when the GluRf subunit is expressed together with one
of the four GluRe subunits in Xenopus oocytes and mammalian
cells [27–30]. Four GluRe subunits are major determinants of the
functional properties of NMDA receptor channels [31]. Noncom-
petitive NMDA receptor antagonists (i.e., PCP, ketamine, and
SKF-10,047) block the four GluRe/GluRf channels to similar
extents in Xenopus oocytes [32]. Gene-targeting techniques provide
an efficient method for clarifying the distinct functions of these
NMDA receptor channel subunits. GluRe1 knockout mice display
increased locomotor activity, whereas GluRe4 knockout mice
exhibit reduced locomotor activity in a novel environment [33–
36]. GluRe3 knockout mice show few apparent deficits [37–39].
Investigating the physiological functions of GluRf or GluRe2
knockout mice, in contrast, is nearly impossible because these two
mutants die shortly after birth [40–42].
To clarify the contributions of NMDA receptor channel subunits
in the PCP-induced increases in extracellular levels of dopamine
(DAex) and locomotor responses,we investigated the effects of METH
and PCPon DAexin the striatum and prefrontal cortex (PFC) using in
vivo microdialysis and measuring locomotor activity in GluRe1
knockout (GluRe1
2/2)a n dG l u R e4k n o c k o u t( G l u R e4
2/2)m i c e .
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Baseline DAex in the striatum and PFC in GluRe1
2/2 and
GluRe4
2/2 mice
Baseline DAex was not different between wildtype, GluRe1
2/2,
and GluRe4
2/2 mice in the striatum (one-way analysis of variance
[ANOVA]: F2,67=0.412, p=0.664) and PFC (one-way ANOVA:
F2,59=1.025, p=0.365). Mean baseline DAex in the striatum was
51.8963.57 fmol/10 ml( n=27) for wildtype, 49.3565.35 fmol/
10 ml( n=19) for GluRe1
2/2, and 46.7563.93 fmol/10 ml
(n=24) for GluRe4
2/2 mice. Mean baseline DAex in the PFC
was 1.2960.20 fmol/10 ml( n=23) for wildtype, 1.5960.30 fmol/
10 ml( n=20) for GluRe1
2/2, and 1.1060.21 fmol/10 ml( n=19)
for GluRe4
2/2 mice.
Effects of acute METH administration on DAex in the
striatum and PFC in GluRe1
2/2 and GluRe4
2/2 mice
Methamphetamine (1 mg/kg) markedly increased DAex in the
striatum and PFC in wildtype, GluRe1
2/2, and GluRe4
2/2 mice
(Fig. 1A, C). Two-way ANOVA (drug 6 genotype) of DAex,
measured as the area-under-the-curve (AUC) calculated during a
180 min posttreatment period, revealed a significant effect of drug
(F1,39=47.418, p,0.001) but not genotype (F2,39= 0.889,
p=0.419) and no significant drug 6 genotype interaction
(F2,39=0.739, p=0.484) in the striatum (Fig. 1B). Similarly, in
the PFC, two-way ANOVA (drug 6 genotype) of AUC values
revealed a significant effect of drug (F1,31=48.784, p,0.001) but
not genotype (F2,31=0.320, p=0.728) and no significant drug 6
genotype interaction (F2,31=0.201, p=0.819) (Fig. 1B).
Effects of acute PCP administration on DAex in the
striatum and PFC in GluRe1
2/2 and GluRe4
2/2 mice
Phencyclidine (3 mg/kg) markedly increased DAex in wildtype
and GluRe1
2/2 mice, but not in GluRe4
2/2 mice, in the
striatum and PFC (Fig. 2A, C). Two-way ANOVA (drug 6
genotype) of AUC values revealed a significant effect of drug
(F1,39=17.201, p,0.001) but not genotype (F2,39=2.012,
p=0.147) in the striatum and a significant drug 6 genotype
interaction (F2,39=3.314, p=0.047) (Fig. 2B). Post hoc comparisons
revealed that the effect of PCP on DAex in GluRe4
2/2 mice was
significantly less compared with wildtype and GluRe1
2/2 mice
(p=0.002 and 0.03, respectively; Fisher’s Protected Least
Significant Difference [PLSD] post hoc test) in the striatum
(Fig. 2B). In the PFC, two-way ANOVA (drug 6 genotype) of
AUC values revealed a significant effect of drug (F1,37=35.215,
p,0.001) but not genotype (F2,37=1.969, p=0.154) and a
significant drug 6 genotype interaction (F2,37=3.326, p=0.047)
(Fig. 2D). Post hoc comparisons revealed that the effect of PCP on
DAex in GluRe4
2/2 mice was significantly less compared with
wildtype and GluRe1
2/2 mice (p=0.007 and 0.003, respectively;
Fisher’s PLSD post hoc test) in the PFC (Fig. 2D).
Locomotor activity in GluRe1
2/2 and GluRe4
2/2 mice in
a novel environment
Locomotor activity in a novel environment was different
between wildtype, GluRe1
2/2, and GluRe4
2/2 mice during the
habituation period (mixed-design ANOVA: genotype,
F2,123=35.423, p,0.0001; time, F2,123=486.554, p,0.0001;
genotype 6time, F4,123=15.337, p,0.0001) (Fig. 3). Locomotor
activity in a novel environment during the 60 min period
increased in GluRe1
2/2 mice (p=0.0002, unpaired t-test) but
decreased in GluRe4
2/2 mice (p,0.0001, Student’s t-test)
compared with wildtype mice. GluRe1
2/2 mice did not habituate
during the 180 min period compared with wildtype mice
(p,0.0001, Student’s t-test).
Effects of acute administration of METH and PCP on
locomotor activity in GluRe1
2/2 and GluRe4
2/2 mice
Two-way ANOVA (drug6genotype) of locomotor activity data
during the 60 min period revealed significant effects of drug
Figure 1. Effects of acute METH on DAex in the striatum and PFC in wildtype, GluRe1
2/2, and GluRe4
2/2 mice. (A, C) Temporal pattern
of DAex before and after s.c. saline (Sal) or METH (1 mg/kg) injection. The arrows indicate the drug injection time. Each point represents the mean 6
SEM of the percentage of DAex baseline. (B, D) Histogram representing the mean AUC 6 SEM of DAex during the 180 min period after saline or METH
injection (n=5–9). **p,0.01, ***p,0.001, compared with saline group of the same genotype (two-way ANOVA followed by Fisher’s PLSD post hoc
test).
doi:10.1371/journal.pone.0013722.g001
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p,0.0001) and a significant drug 6 genotype interaction
(F4,155=5.734, p=0.0002) (Fig. 4). Methamphetamine (1 mg/kg)
significantly increased locomotor activity during the 60 min period
after the METH injection in wildtype mice (p=0.002, Student’s t-
test) and GluRe4
2/2 mice (p=0.0004, Student’s t-test) compared
with saline. However, METH (1 mg/kg) did not increase
locomotor activity during the 60 min period after the METH
injection in GluRe1
2/2 mice (p=0.411, Student’s t-test) com-
pared with saline.
Phencyclidine (3 mg/kg) significantly increased locomotor
activity during the 60 min period after the PCP injection in
wildtype mice (p=0.008, Student’s t-test) and GluRe1
2/2 mice
(p=0.045, Student’s t-test) compared with saline treatment.
However, PCP (3 mg/kg) did not increase locomotor activity in
GluRe4
2/2 mice (p=0.142, unpaired t-test) compared with saline
treatment.
Effects of repeated administration of METH and PCP on
locomotor activity in GluRe1
2/2 and GluRe4
2/2 mice
Mixed-design ANOVA of locomotor activity data during the
60 min period after the METH injection from Session 1 to 8
revealed significant effects of genotype (F2,385=3.350, p=0.042)
and session (F7,385=16.091, p,0.0001) but no significant genotype
6session interaction (F14,385=0.611, p=0.857) (Fig. 5A). Chronic
METH (1 mg/kg) injections increased locomotor activity in
wildtype (p,0.0001, paired t-test), GluRe1
2/2 (p=0.0007, paired
t-test), and GluRe4
2/2 mice (p=0.0001, paired t-test) in Session 1
compared with Session 8.
Mixed-design ANOVA of locomotor activity data during the
60 min period after the PCP injection revealed a significant effect
of genotype (F2,455=11.318, p,0.0001) but not session
(F7,455=1.443, p=0.186) and a significant genotype 6 session
interaction (F14,455=2.368, p=0.0035) (Fig. 5B). Phencyclidine-
induced hyperactivity was significantly greater in Session 8 than
Session 1 in wildtype mice (p=0.006, paired t-test). Repeated PCP
(3 mg/kg) administration did not increase locomotor activity in
GluRe1
2/2 mice (p=0.121, paired t-test) and GluRe4
2/2 mice
(p=0.605, paired t-test) in Session 1 compared with Session 8.
Figure 2. Effects of acute PCP on DAex in the striatum and PFC in wildtype, GluRe1
2/2, and GluRe4
2/2 mice. (A, C) Temporal pattern of
DAex before and after s.c. saline (Sal) or PCP (3 mg/kg) injection. The arrows indicate the drug injection time. Each point represents the mean 6 SEM
of the percentage of DAex baseline. (B, D) Histogram representing the mean AUC 6 SEM of DAex during the 180 min period after saline or PCP
injection (n=5–11). ***p,0.001, compared with saline group of the same genotype;
#p,0.05,
##p,0.01, comparisons between genotypes in the
same drug treatment (two-way ANOVA followed by Fisher’s PLSD post hoc test).
doi:10.1371/journal.pone.0013722.g002
Figure 3. Locomotor activity in wildtype, GluRe1
2/2,a n d
GluRe4
2/2 mice in a novel environment. Locomotor activity was
measured for 180 min. Each point represents the mean 6 SEM (n=34–
50). *p,0.05, **p,0.01, ***p,0.001, compared with wildtype mice
(one-way ANOVA followed by Fisher’s PLSD post hoc test).
doi:10.1371/journal.pone.0013722.g003
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The present study showed that PCP-induced increases in DAex
in the striatum and PFC and locomotor activity were absent in
GluRe4
2/2, but present in GluRe1
2/2, mice, indicating that
GluRe4 plays an important role in PCP-increased DAex and
locomotor activity. Phencyclidine exerts psychotomimetic effects,
whereas another NMDA receptor antagonist, MK-801, exerts no
clear psychotomimetic effects in humans [43]. Interestingly,
whereas MK-801 suppresses GluRe3/GluRf1 and GluRe4/
GluRf1 channels more weakly than GluRe1/GluRf1 and
GluRe2/GluRf1 channels, PCP blocks the four GluRe/GluRf
channels to similar extents in Xenopus oocytes [32]. The absence of
psychotomimetic effects of MK-801 may be attributable to its
weak ability of blocking the GluRe4/GluRf1 channel.
Systemic administration of PCP reportedly increases DAex in
the striatum and PFC [44–49]. Similarly, PCP (3 mg/kg)
increased DAex in wildtype and GluRe1
2/2 mice in the present
study. However, PCP failed to increase DAex in the striatum and
PFC in GluRe4
2/2 mice. Phencyclidine is known to be a DA
reuptake blocker and a noncompetitive NMDA antagonist [9–11].
It inhibits DA uptake by binding to the DAT at doses
approximately 10-fold greater than those at which it binds to
NMDA receptor channels [1]. Phencyclidine at the low dose used
in the present study appears to have few effects on the DAT.
Furthermore, no PCP-induced increases in DAex in GluRe4
2/2
mice that possess an intact DAT gene indicates that PCP increases
DAex not via DAT inhibition but via blockade of NMDA receptor
channels. The present results support the hypothesis that GluRe4
is an important determinant of increased DAex induced by PCP.
Acute administration of METH increased DAex in the striatum
and PFC in wildtype, GluRe1
2/2, and GluRe4
2/2 mice. No
differences in DAex increases were found between genotypes. The
similar DAex increases among these mice in response to acute
METH challenge suggest that increased DAex occurs indepen-
dently of GluRe1
2/2 and GluRe4
2/2.
Locomotor activity in a novel environment is reportedly high in
GluRe1
2/2 mice [34,36] and low in GluRe4
2/2 mice [33,35].
Consistent with these findings, increased locomotor activity in
GluRe1
2/2 mice and reduced locomotor activity in GluRe4
2/2
mice were observed in the present study. GluRe1
2/2 mice did not
habituate during the 180 min period compared with wildtype
mice. Interestingly, acute METH administration decreased
locomotor activity in GluRe1
2/2 mice. Hyperactivity and a
paradoxical response to METH suggest that GluRe1
2/2 mice
may be an animal model of attention-deficit/hyperactivity
disorder.
Psychostimulants, such as METH and PCP, increase locomotor
activity [2,3,12,13]. In GluRe4
2/2 mice, acute METH adminis-
tration increased locomotor activity, but PCP did not. Acute PCP
administration increased locomotor activity in wildtype and
GluRe1
2/2 mice, but not in GluRe4
2/2 mice. The absence of
locomotor-stimulating effects of PCP in GluRe4
2/2 mice indicates
that locomotor responses to PCP require the GluRe4 subunit.
Repeated administration of PCP produces sensitization to its
locomotor-stimulating effects in wildtype mice. In GluRe4
2/2
mice, locomotor activity did not increase after repeated PCP
treatment. Acute PCP did not increase locomotor activity, and
repeated PCP did not produce sensitization to the locomotor-
stimulating effects of PCP in GluRe4
2/2 mice. The GluRe4
subunit appears to be necessary for behavioral sensitization to
occur in response to repeated PCP administration. A previous
study demonstrated that acute PCP treatment increased locomotor
activity in wildtype and GluRe1
2/2 mice. Chronic PCP treatment
at a low dose (3 mg/kg/day) for 7 days produced sensitization to
the locomotor-stimulating effects of PCP in wildtype mice, but not
Figure 4. Effects of acute METH and PCP on the locomotor
activity in GluRe1
2/2 and GluRe4
2/2 mice. Locomotor activity after
acute saline, METH (1 mg/kg), or PCP (3 mg/kg) administration (n=10–
25). *p,0.05, **p,0.01, compared with saline (Student’s t-test);
#p,0.05,
##p,0.01, compared with wildtype (Student’s t-test).
doi:10.1371/journal.pone.0013722.g004
Figure 5. Effects of repeated METH and PCP on the locomotor
activity in GluRe1
2/2 and GluRe4
2/2 mice. Changes in response to
repeated administration of (A) METH (1 mg/kg) or (B) PCP (3 mg/kg)
(n=15–25). *p,0.05, **p,0.01, ***p,0.001, compared with Session 1
of the same genotype (paired t-test). Each point represents total
locomotor activity (mean 6 SEM) during the 60 min period after METH
or PCP injection.
doi:10.1371/journal.pone.0013722.g005
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2/2 mice [50]. The present study confirmed that
repeated PCP administration (3 mg/kg/day) did not produce
sensitization during Session 8 in GluRe1
2/2 mice. Repeated
METH administration produced behavioral sensitization in wild-
type, GluRe1
2/2, and GluRe4
2/2 mice. The development of
sensitization in GluRe1
2/2 and GluRe4
2/2 mice was delayed
compared with wildtype mice. The noncompetitive NMDA
receptor antagonist MK-801 has been shown to block the
development of behavioral sensitization to AMPH and METH
[51–54]. Molecular and cellular adaptive changes during chronic
drug exposure are hypothesized to lead to the development of
sensitization. Our findings support the hypothesis that adaptive
changes through NMDA receptor channels play a role in the
development of locomotor sensitization to METH.
Schizophrenia is a disease that has been hypothesized to be
associated with hyperfunction of the dopaminergic neuronal
system and dysfunction of glutamatergic transmission [55,56].
Administration of PCP to normal humans induces symptoms
similar to those of schizophrenia [57]. This finding has been
replicated over the years, and PCP has been shown to exacerbate
the primary symptoms of schizophrenic patients [56]. Phencycli-
dine-treated animals have been used as an animal model of
schizophrenia, and the amelioration of hyperlocomotion in these
animals has been used as a screening test to assess the efficacy of
antipsychotic drugs [58,59]. GluRe4 immunoreactivity and
protein expression increase in the frontal cortex following repeated
PCP treatment, whereas GluRe1 immunoreactivity and protein
expression are not altered in rats [60]. Furthermore, polymor-
phisms of several genes known to interact with NMDA receptor
channels are related to altered risk for schizophrenia, and
psychotic patients display changes in the levels of mRNA encoding
NMDA receptors [61]. Interestingly, Makino et al. reported that
the GluRe4 gene locus is a possible genomic region that
contributes to schizophrenia susceptibility in a Japanese popula-
tion [62]. In the present study, we first demonstrated that deletion
of GluRe4 abolished PCP-induced hyperlocomotion and poten-
tiated the increases in DAex in mice. Our data and previous
findings suggest that GluRe4 might be a potential target for
antipsychotic drug development.
Although NMDA receptor channels are highly expressed in
adult brains, adult GluRe4 expression is very limited [26]. GluRe4
is expressed in the substantia nigra compacta (SNc), subthalamic
nucleus, globus pallidus, and ventral pallidum in adult rats [63].
Jones and Gibb reported that functional GluRe2 and GluRe4
subunits form somatic NMDA receptors, possibly as trihetero-
meric receptors, whereas no somatic GluRe1 subunits are present
in SNc dopaminergic neurons in rats aged postnatal day 14 [64]. A
small subset of NMDA receptor channels (i.e., channels containing
GluRe4) may be implicated in the effects of PCP on DAex and
locomotor activity. This possibility is consistent with the lack of
psychotic effects of ifenprodil, a selective blocker of NMDA
receptor channels containing GluRe2, which is highly expressed in
adult brains. Additionally, GluRe4 is highly expressed in the brain
during development [26], suggesting that GluRe4 knockout during
the developmental stage may alter neuronal function in the adult
brain. Although the expression of the genes related to dopami-
nergic signaling pathways are not altered in GluRe4
2/2 mice
during adulthood (see Table S1), other developmental changes
may alter the effects of PCP in GluRe4
2/2 mice. Further studies
of synapses, neurons, and neuronal networks regulated by GluRe4
and developmental changes in neuronal function in GluRe4
2/2
mice may lead to a better understanding of the mechanisms
underlying PCP-induced psychosis and schizophrenia.
Materials and Methods
Ethics statement
The experimental procedures and housing conditions were
approved by the Institutional Animal Care and Use Committee
(Animal Experimentation Ethics Committee of Tokyo Institute of
Psychiatry, Approval ID: 22-2), and all animal were cared for and
treated humanely in accordance with our institutional animal
experimentation guidelines.
Animals
Wildtype and GluRe1
2/2 or GluRe4
2/2 mouse littermates
from crosses of heterozygous/heterozygous GluRe1 or GluRe4
knockout mice, respectively, on a C57BL/6 genetic background
[33,65] served as subjects. Naive adult mice were housed in an
animal facility maintained at 2262uC and 5565% relative
humidity under a 12 h/12 h light/dark cycle with lights on at
8:00 am and off at 8:00 pm. Food and water were available ad
libitum. In the behavioral experiments, 13- to 23-week-old male
mice were used. In the microdialysis experiments, 10- to 24-week-
old male and female mice were used.
Surgery
Microdialysis probes were stereotaxically implanted in mice
under sodium pentobarbital anesthesia (50 mg/kg, intraperitone-
ally) in the striatum (anterior, +0.6 mm; lateral, +1.8 mm; ventral,
24.0 mm from bregma) or PFC (anterior, +2.0 mm; lateral,
+0.5 mm; ventral 23.0 mm from bregma), according to the atlas
of Franklin and Paxinos [66]. The probe tip was constructed with
a regenerated cellulose membrane (outer diameter, 0.22 mm;
membrane length, 2 mm; Eicom, Kyoto, Japan). All dialysis probe
placements were verified histologically at the completion of the
experiment.
Microdialysis and analytical procedures
Twenty-four hours after implantation, the dialysis experiments
were performed in freely moving animals. Ringer’s solution
(145 mM NaCl, 3 mM KCl, 1.26 mM CaCl2, and 1 mM MgCl2,
pH 6.5) was perfused at a constant flow rate of 1 ml/min.
Perfusates were directly injected into the high-performance liquid
chromatography system every 10 min using an autoinjector (EAS-
20; Eicom). Dialysate DA was separated using a reverse-phase
ODS column (PP-ODS; Eicom) and detected with a graphite
electrode (HTEC-500; Eicom). The mobile phase consisted of
0.1 M phosphate buffer (pH 5.5) containing 500 mg/l sodium
decanesulfonate, 50 mg/l EDTA, and 1% methanol. Perfusion
was initiated 180 min prior to the collection of baseline samples.
Baseline levels of DAex were obtained from the average
concentrations of three consecutive samples when they were
stable. The DA detection limit of the assay was 0.3 fmol/sample
with a signal-to-noise ratio of 2.
Locomotor activity measurements
Each mouse were exposed to an illuminated chamber
(30640625 cm) at an ambient temperature of 2262uC, and
locomotor activity was measured with Supermex (Muromachi
Kikai, Tokyo, Japan), a sensor monitor mounted above the
chamber. In this system, a sensor detects the radiated body heat of
an animal [67]. This measurement system can detect changes in
heat across multiple zones of the chamber and count all horizontal
movements. All counts were automatically summed and recorded
every 5 min. After a 180 min habituation period, METH or PCP
was administered subcutaneously (s.c.), and locomotor activity was
monitored continuously for 180 min.
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Drugs were dissolved in saline and administered s.c. in a volume
of 10 ml/kg. In the microdialysis experiment, saline, METH
(1 mg/kg), or PCP (3 mg/kg) was administered after establishing a
stable baseline, and the dialysate was continuously collected for
180 min. In the acute behavioral experiments, saline, freshly
prepared METH (1 mg/kg; Dainippon Sumitomo Pharma,
Osaka, Japan), or PCP (3 mg/kg; Shionogi Pharmaceutical Co.
Ltd., Osaka, Japan) was administered. In the repeated behavioral
experiments, METH (1 mg/kg) or PCP (3 mg/kg) was adminis-
tered repeatedly at 2 or 3 day intervals for a total of seven
injections. One week after withdrawal, METH or PCP challenge
injections were administered as described above.
Statistical analysis
DAex responses to drugs are expressed as a percentage of
baseline. The AUC of DAex during the 180 min period after drug
administration was calculated as the effects of the drugs. Area-
under-the-curve values of all groups were analyzed using two-way
ANOVA. Individual post hoc comparisons were performed with
Fisher’s PLSD test. The responses to acute administration were
analyzed using Student’s t-test, one-way ANOVA, or two-way
ANOVA. To evaluate behavioral sensitization, the response to
drugs in Session 8 was compared with the response to the first drug
injection (Session 1) in the same animal using a paired t-test or
mixed-design ANOVA. Values of p,0.05 were considered
statistically significant. Data were analyzed using Statview J5.0
software (SAS Institute, Cary, NC, USA).
Supporting Information
Table S1 Striatal gene expression in wildtype and GluRe4-/-
mice.
Found at: doi:10.1371/journal.pone.0013722.s001 (0.03 MB
DOC)
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